In this podcast, two experts discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC. Claim your credit at pce.is/GIGU.
In this first episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies and the evolving treatment landscape in HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Amit Singal, MD, MS
Mark Yarchoan, MD
Bridget O’Brien, DNP, FNP-BC, AOCNP
Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.
Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.
Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.